Programs

Clinical & Commercial Programs

AIVITA’s lead therapeutic focus is a patient-specific immunotherapy for the treatment of advanced cancers, currently being investigated in glioblastoma and melanoma. We are also developing a personalized vaccine for the prevention of COVID-19.

Cancer

Patient-specific dendritic cell, tumor cell immunotherapy for the treatment of glioblastoma and melanoma.

SARS-CoV-2

Patient-specific dendritic cell vaccine for the prevention of SARS-CoV-2.

 

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Commercialization

Glioblastoma (Phase 2)

Cancer: Glioblastoma (Phase 2)

Melanoma (Phase 1B)

Melanoma (Phase 1B)

SARS-CoV-2 (Phase 2)

SARS-CoV-2 (Phase 2)

Retinal Degeneration (Preclinical)

Retinal Degeneration (Preclinical)